DXCM's Quality Score fell 1 point on Tue, Nov 3, to 14. It closed away from its high of the day.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 40% in a year while the S&P 500 rose 11%.
| Since its Nov 2021 high | Down 48% |
| Latest filing | 8-K, Oct 29 |
After its last 4 reports it closed +6.4% on average, higher 4 of 4 times.
Above Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
DXCM is #9 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 9 |
Share count against a year before: DXCM -2.5%, MMED +11%, PEN +1.3%, BAX +0.8%.
Expected to report Thu Feb 11, after the close (in 100 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $1.3B, 11% more than a year ago; a profit of $0.72 a share, from $0.70.
DXCM's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Revenue | $5.20B to $5.25B |
Sales grew 19% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 0.7% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | +2.0% | +3.0% | open |
| Jul 30, 2026 | +7.2% | +11.9% | +11.4% |
| Apr 30, 2026 | +2.4% | +3.0% | +2.3% |
Sales grew every year from 2018 to 2025, to $4.7B. It made a profit in seven of the eight years.
19 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: DXCM is 0.2% of JEPQ, 0.2% of QQQI, and 0.2% of QQQ, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
“The market for glucose monitoring devices is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants.”
DXCM scores 14 today, which Breakaway calls Above Average. It is #9 of 85 in Medical Devices by Quality Score, with 1 of 14 chart checks firing. Up 40% in a year while the S&P 500 rose 11%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
DXCM scores 14 today, which Breakaway calls Above Average (11 to 14). That is #9 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DXCM's 14.
Expected to report Thu Feb 11, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. DXCM closed higher after 4 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.